Paid Clinical Trials Aurora
Discover 1,529 paid clinical trials in Aurora, Colorado. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Study of Olutasidenib and Temozolomide in HGGStudy of Olutasidenib and Temozolomide in HGG
Sponsor:
Rigel Pharmaceuticals
Location:
Code:
NCT06161974
Conditions
High Grade Glioma
Astrocytoma
Astrocytoma, Grade III
Astrocytoma, Grade IV
Diffuse Intrinsic Pontine Glioma
Eligibility Criteria
Sex: All
Age: 12 - 39
Healthy Volunteers: Not accepted
Interventions
Olutasidenib + TMZ
Safety and Effectiveness of the PXL-Platinum 330 SystemSafety and Effectiveness of the PXL-Platinum 330 System
Sponsor:
Colorado Eye Consultants/Cornea Consultants of Colorado
Location:
Code:
NCT04401865
Conditions
Corneal Ectasia
Keratoconus
Pellucid Marginal Corneal Degeneration
Eligibility Criteria
Sex: All
Age: 8+
Healthy Volunteers: Not accepted
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder CancerA Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Sponsor:
Janssen Research & Development, LLC
Location:
Code:
NCT06319820
Conditions
Non-Muscle Invasive Bladder Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
TAR-210
Gemcitabine
MMC
SynKIR-310 for Relapsed/Refractory B-NHLSynKIR-310 for Relapsed/Refractory B-NHL
Sponsor:
Verismo Therapeutics
Location:
Code:
NCT06544265
Conditions
B Cell Lymphoma
NHL, Adult
Mantle Cell Lymphoma
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
SynKIR-310
Innovations in Hearing Accessibility and Technology (IHAT) StudyInnovations in Hearing Accessibility and Technology (IHAT) Study
Sponsor:
University of Colorado, Denver
Location:
Code:
NCT06689865
Conditions
Hearing Loss
Hearing Aids
OTC Hearing Aids
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Interventions
HA-HCP
OTC-HCP
OTC-R
OTC-SF
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)
Sponsor:
Biogen
Location:
Code:
NCT05531565
Conditions
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Litifilimab
Placebo
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaThoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Sponsor:
Children's Oncology Group
Location:
Code:
NCT05235165
Conditions
Metastatic Malignant Neoplasm in the Lung
Metastatic Osteosarcoma
Osteosarcoma
Eligibility Criteria
Sex: All
Age: 0 - 50
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Questionnaire Administration
Thoracoscopy
Thoracotomy
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid TumorsA Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Sponsor:
Jubilant Therapeutics Inc.
Location:
Code:
NCT05268666
Conditions
Locally Advanced Solid Tumor
Metastatic Solid Tumor
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
JBI-802
A Study of NX-1607 in Adults With Advanced MalignanciesA Study of NX-1607 in Adults With Advanced Malignancies
Sponsor:
Nurix Therapeutics, Inc.
Location:
Code:
NCT05107674
Conditions
Ovarian Cancer, Epithelial
Gastric Cancer
GastroEsophageal Junction (GEJ) Cancer
Head and Neck Squamous Cell Carcinoma
Metastatic or Unresectable Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
NX-1607
Paclitaxel
Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.
Sponsor:
University of Colorado, Denver
Location:
Code:
NCT03958565
Conditions
Carcinoma, Non-Small-Cell Lung
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Tyrosine Kinase Inhibitor
Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]
Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]